An open-label, multicenter, single-arm, post-marketing trial (in select countries) to evaluate efficacy and safety and the impact of immunogenicity on efficacy, safety, and pharmacokinetics of spesolimab i.v. in treatment of patients with Generalized Pustular Psoriasis presenting with a recurrent flare following their initial GPP flare treatment with spesolimab i.v - NIL
A Phase 3, randomised, double-blind, parallel-group, eventdriven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weightrelated complications or risk factors for CVD - NIL
A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin soluble solid dispersion (ssd) tablets for the delay of encephalopathy decompensation in cirrhosis (red-c) - NIL
100 Clinical Results associated with IQVIA RDS (India) Pvt Ltd.
0 Patents (Medical) associated with IQVIA RDS (India) Pvt Ltd.
100 Deals associated with IQVIA RDS (India) Pvt Ltd.
100 Translational Medicine associated with IQVIA RDS (India) Pvt Ltd.